Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Parathyroid hormone-like hormone plays a dual role in neuroblastoma depending on PTH1R expression.

García M, Rodríguez-Hernández CJ, Mateo-Lozano S, Pérez-Jaume S, Gonçalves-Alves E, Lavarino C, Mora J, de Torres C.

Mol Oncol. 2019 Jul 10. doi: 10.1002/1878-0261.12542. [Epub ahead of print]

2.

Old drugs still work! Oral etoposide in a relapsed medulloblastoma.

Perez-Somarriba M, Andión M, López-Pino MA, Lavarino C, Madero L, Lassaletta A.

Childs Nerv Syst. 2019 May;35(5):865-869. doi: 10.1007/s00381-019-04072-9. Epub 2019 Feb 1.

PMID:
30707305
3.

Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01.

Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K, Correa G, Paco S, Vila-Ubach M, Cuadrado-Vilanova M, Castillo-Ecija H, Botteri G, Garcia-Gerique L, Moreno-Gilabert H, Gimenez-Alejandre M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, Doz F, Cassoux N, Chapeaublanc E, Torrebadell M, Roldan M, König A, Suñol M, Claverol J, Lavarino C, Carmen de T, Fu L, Radvanyi F, Munier FL, Catalá-Mora J, Mora J, Alemany R, Cascalló M, Chantada GL, Carcaboso AM.

Sci Transl Med. 2019 Jan 23;11(476). pii: eaat9321. doi: 10.1126/scitranslmed.aat9321.

PMID:
30674657
4.

The molecular landscape of glioma in patients with Neurofibromatosis 1.

D'Angelo F, Ceccarelli M, Tala, Garofano L, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Kamiya-Matsuoka C, Lavarino C, Loiseau H, Lorgis V, Marras CE, McCutcheon I, Nam DH, Ronchi S, Saletti V, Seizeur R, Slopis J, Suñol M, Vandenbos F, Varlet P, Vidaud D, Watts C, Tabar V, Reuss DE, Kim SK, Meyronet D, Mokhtari K, Salvador H, Bhat KP, Eoli M, Sanson M, Lasorella A, Iavarone A.

Nat Med. 2019 Jan;25(1):176-187. doi: 10.1038/s41591-018-0263-8. Epub 2018 Dec 10.

PMID:
30531922
5.

Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq.

Filbin MG, Tirosh I, Hovestadt V, Shaw ML, Escalante LE, Mathewson ND, Neftel C, Frank N, Pelton K, Hebert CM, Haberler C, Yizhak K, Gojo J, Egervari K, Mount C, van Galen P, Bonal DM, Nguyen QD, Beck A, Sinai C, Czech T, Dorfer C, Goumnerova L, Lavarino C, Carcaboso AM, Mora J, Mylvaganam R, Luo CC, Peyrl A, Popović M, Azizi A, Batchelor TT, Frosch MP, Martinez-Lage M, Kieran MW, Bandopadhayay P, Beroukhim R, Fritsch G, Getz G, Rozenblatt-Rosen O, Wucherpfennig KW, Louis DN, Monje M, Slavc I, Ligon KL, Golub TR, Regev A, Bernstein BE, Suvà ML.

Science. 2018 Apr 20;360(6386):331-335. doi: 10.1126/science.aao4750.

6.

A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.

Gómez S, Garrido-Garcia A, Garcia-Gerique L, Lemos I, Suñol M, de Torres C, Kulis M, Pérez-Jaume S, Carcaboso ÁM, Luu B, Kieran MW, Jabado N, Kozlenkov A, Dracheva S, Ramaswamy V, Hovestadt V, Johann P, Jones DTW, Pfister SM, Morales La Madrid A, Cruz O, Taylor MD, Martin-Subero JI, Mora J, Lavarino C.

Clin Cancer Res. 2018 Mar 15;24(6):1355-1363. doi: 10.1158/1078-0432.CCR-17-2243. Epub 2018 Jan 19.

7.

Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

Monterrubio C, Paco S, Olaciregui NG, Pascual-Pasto G, Vila-Ubach M, Cuadrado-Vilanova M, Ferrandiz MM, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NKV, Mora J, Sosnik A, Carcaboso AM.

J Control Release. 2017 Jun 10;255:108-119. doi: 10.1016/j.jconrel.2017.04.016. Epub 2017 Apr 12.

8.

EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.

Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT, Tvardovskiy A, Jensen ON, Olaciregui NG, Lavarino C, Suñol M, de Torres C, Mora J, Carcaboso AM, Helin K.

Nat Med. 2017 Apr;23(4):483-492. doi: 10.1038/nm.4293. Epub 2017 Feb 27.

PMID:
28263309
9.

Genetic variants in the promoter region of the calcium-sensing receptor gene are associated with its down-regulation in neuroblastic tumors.

Masvidal L, Iniesta R, García M, Casalà C, Lavarino C, Mora J, de Torres C.

Mol Carcinog. 2017 Apr;56(4):1281-1289. doi: 10.1002/mc.22589. Epub 2016 Nov 24.

PMID:
27862333
10.

Infratentorial congenital glioblastoma multiforme. A rare tumour with a still unknown biology.

Salas S, Agut T, Rovira C, Canizo D, Lavarino C, Garcia-Alix A.

Rev Neurol. 2016 Nov 1;63(9):411-414. Spanish, English.

11.

Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination.

Pascual-Pasto G, Olaciregui NG, Vila-Ubach M, Paco S, Monterrubio C, Rodriguez E, Winter U, Batalla-Vilacis M, Catala J, Salvador H, Parareda A, Schaiquevich P, Suñol M, Mora J, Lavarino C, de Torres C, Chantada GL, Carcaboso AM.

Cancer Lett. 2016 Sep 28;380(1):10-9. doi: 10.1016/j.canlet.2016.06.012. Epub 2016 Jun 16.

PMID:
27319373
12.

RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein.

Hernandez-Muñoz I, Figuerola E, Sanchez-Molina S, Rodriguez E, Fernández-Mariño AI, Pardo-Pastor C, Bahamonde MI, Fernández-Fernández JM, García-Domínguez DJ, Hontecillas-Prieto L, Lavarino C, Carcaboso AM, de Torres C, Tirado OM, de Alava E, Mora J.

Oncotarget. 2016 Jul 19;7(29):46283-46300. doi: 10.18632/oncotarget.10092.

13.

Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens.

Rodríguez-Hernández CJ, Mateo-Lozano S, García M, Casalà C, Briansó F, Castrejón N, Rodríguez E, Suñol M, Carcaboso AM, Lavarino C, Mora J, de Torres C.

Oncotarget. 2016 Mar 29;7(13):16112-29. doi: 10.18632/oncotarget.7448.

14.

DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights.

Gómez S, Castellano G, Mayol G, Queiros A, Martín-Subero JI, Lavarino C.

Genom Data. 2015 Jul 17;5:360-3. doi: 10.1016/j.gdata.2015.07.016. eCollection 2015 Sep.

15.

DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights.

Gómez S, Castellano G, Mayol G, Suñol M, Queiros A, Bibikova M, Nazor KL, Loring JF, Lemos I, Rodríguez E, de Torres C, Mora J, Martín-Subero JI, Lavarino C.

Epigenomics. 2015 Oct;7(7):1137-53. doi: 10.2217/epi.15.49. Epub 2015 Jun 12.

16.

Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts.

Monterrubio C, Paco S, Vila-Ubach M, Rodríguez E, Glisoni R, Lavarino C, Schaiquevich P, Sosnik A, Mora J, Carcaboso AM.

Pharm Res. 2015 Sep;32(9):2889-900. doi: 10.1007/s11095-015-1671-9. Epub 2015 Mar 14.

PMID:
25773723
17.

Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).

Mora J, Cruz O, Lavarino C, Rios J, Vancells M, Parareda A, Salvador H, Suñol M, Carrasco R, Guillen A, Mañé S, de Torres C.

Clin Transl Oncol. 2015 Jul;17(7):521-9. doi: 10.1007/s12094-014-1273-8. Epub 2015 Jan 17.

PMID:
25596034
18.

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.

Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, Helman E, Taylor-Weiner A, McKenna A, DeLuca DS, Lawrence MS, Ambrogio L, Sougnez C, Sivachenko A, Walensky LD, Wagle N, Mora J, de Torres C, Lavarino C, Dos Santos Aguiar S, Yunes JA, Brandalise SR, Mercado-Celis GE, Melendez-Zajgla J, Cárdenas-Cardós R, Velasco-Hidalgo L, Roberts CW, Garraway LA, Rodriguez-Galindo C, Gabriel SB, Lander ES, Golub TR, Orkin SH, Getz G, Janeway KA.

Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5564-73. doi: 10.1073/pnas.1419260111. Epub 2014 Dec 15.

19.

The genomic landscape of pediatric Ewing sarcoma.

Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, Kiezun A, Carter SL, Shukla SA, Mehta SS, Thorner AR, de Torres C, Lavarino C, Suñol M, McKenna A, Sivachenko A, Cibulskis K, Lawrence MS, Stojanov P, Rosenberg M, Ambrogio L, Auclair D, Seepo S, Blumenstiel B, DeFelice M, Imaz-Rosshandler I, Schwarz-Cruz Y Celis A, Rivera MN, Rodriguez-Galindo C, Fleming MD, Golub TR, Getz G, Mora J, Stegmaier K.

Cancer Discov. 2014 Nov;4(11):1326-41. doi: 10.1158/2159-8290.CD-13-1037. Epub 2014 Sep 3.

20.

Cytogenetic prognostication within medulloblastoma subgroups.

Shih DJ, Northcott PA, Remke M, Korshunov A, Ramaswamy V, Kool M, Luu B, Yao Y, Wang X, Dubuc AM, Garzia L, Peacock J, Mack SC, Wu X, Rolider A, Morrissy AS, Cavalli FM, Jones DT, Zitterbart K, Faria CC, Schüller U, Kren L, Kumabe T, Tominaga T, Shin Ra Y, Garami M, Hauser P, Chan JA, Robinson S, Bognár L, Klekner A, Saad AG, Liau LM, Albrecht S, Fontebasso A, Cinalli G, De Antonellis P, Zollo M, Cooper MK, Thompson RC, Bailey S, Lindsey JC, Di Rocco C, Massimi L, Michiels EM, Scherer SW, Phillips JJ, Gupta N, Fan X, Muraszko KM, Vibhakar R, Eberhart CG, Fouladi M, Lach B, Jung S, Wechsler-Reya RJ, Fèvre-Montange M, Jouvet A, Jabado N, Pollack IF, Weiss WA, Lee JY, Cho BK, Kim SK, Wang KC, Leonard JR, Rubin JB, de Torres C, Lavarino C, Mora J, Cho YJ, Tabori U, Olson JM, Gajjar A, Packer RJ, Rutkowski S, Pomeroy SL, French PJ, Kloosterhof NK, Kros JM, Van Meir EG, Clifford SC, Bourdeaut F, Delattre O, Doz FF, Hawkins CE, Malkin D, Grajkowska WA, Perek-Polnik M, Bouffet E, Rutka JT, Pfister SM, Taylor MD.

J Clin Oncol. 2014 Mar 20;32(9):886-96. doi: 10.1200/JCO.2013.50.9539. Epub 2014 Feb 3.

21.

Identification of a putative transcriptome signature common to neuroblastoma and neural crest cells.

Rabadán MA, Usieto S, Lavarino C, Martí E.

Dev Neurobiol. 2013 Nov;73(11):815-27. doi: 10.1002/dneu.22099. Epub 2013 Sep 17.

22.

Polymorphisms in the calcium-sensing receptor gene are associated with clinical outcome of neuroblastoma.

Masvidal L, Iniesta R, Casalà C, Galván P, Rodríguez E, Lavarino C, Mora J, de Torres C.

PLoS One. 2013;8(3):e59762. doi: 10.1371/journal.pone.0059762. Epub 2013 Mar 22.

23.

DNA hypomethylation affects cancer-related biological functions and genes relevant in neuroblastoma pathogenesis.

Mayol G, Martín-Subero JI, Ríos J, Queiros A, Kulis M, Suñol M, Esteller M, Gómez S, Garcia I, de Torres C, Rodríguez E, Galván P, Mora J, Lavarino C.

PLoS One. 2012;7(11):e48401. doi: 10.1371/journal.pone.0048401. Epub 2012 Nov 7.

24.

The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis.

Casalà C, Gil-Guiñón E, Ordóñez JL, Miguel-Queralt S, Rodríguez E, Galván P, Lavarino C, Munell F, de Alava E, Mora J, de Torres C.

Carcinogenesis. 2013 Feb;34(2):268-76. doi: 10.1093/carcin/bgs338. Epub 2012 Oct 29.

PMID:
23108190
25.

A three-gene expression signature model for risk stratification of patients with neuroblastoma.

Garcia I, Mayol G, Ríos J, Domenech G, Cheung NK, Oberthuer A, Fischer M, Maris JM, Brodeur GM, Hero B, Rodríguez E, Suñol M, Galvan P, de Torres C, Mora J, Lavarino C.

Clin Cancer Res. 2012 Apr 1;18(7):2012-23. doi: 10.1158/1078-0432.CCR-11-2483. Epub 2012 Feb 10.

26.

Locoregional MYCN-amplified neuroblastoma.

Morales La Madrid A, Volchenboum S, Gastier-Foster JM, Pyatt R, Liu D, Pytel P, Lavarino C, Rodriguez E, Cohn SL.

Pediatr Blood Cancer. 2012 Oct;59(4):736-8. doi: 10.1002/pbc.24003. Epub 2012 Jan 1.

PMID:
22213566
27.

Identification of tumoral glial precursor cells in neuroblastoma.

Acosta S, Mayol G, Rodríguez E, Lavarino C, de Preter K, Kumps C, Garcia I, de Torres C, Mora J.

Cancer Lett. 2011 Dec 15;312(1):73-81. doi: 10.1016/j.canlet.2011.08.004. Epub 2011 Aug 17.

PMID:
21903323
28.

Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma.

Garcia I, Mayol G, Rodríguez E, Suñol M, Gershon TR, Ríos J, Cheung NK, Kieran MW, George RE, Perez-Atayde AR, Casala C, Galván P, de Torres C, Mora J, Lavarino C.

Mol Cancer. 2010 Oct 15;9:277. doi: 10.1186/1476-4598-9-277.

29.

Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.

De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, Janoueix-Lerosey I, Lavarino C, Maris JM, Mora J, Nakagawara A, Oberthuer A, Ohira M, Schleiermacher G, Schramm A, Schulte JH, Wang Q, Westermann F, Speleman F, Vandesompele J.

Clin Cancer Res. 2010 Mar 1;16(5):1532-41. doi: 10.1158/1078-0432.CCR-09-2607. Epub 2010 Feb 23.

30.

The calcium-sensing receptor and parathyroid hormone-related protein are expressed in differentiated, favorable neuroblastic tumors.

de Torres C, Beleta H, Díaz R, Toran N, Rodríguez E, Lavarino C, García I, Acosta S, Suñol M, Mora J.

Cancer. 2009 Jun 15;115(12):2792-803. doi: 10.1002/cncr.24304.

31.

Comprehensive characterization of neuroblastoma cell line subtypes reveals bilineage potential similar to neural crest stem cells.

Acosta S, Lavarino C, Paris R, Garcia I, de Torres C, Rodríguez E, Beleta H, Mora J.

BMC Dev Biol. 2009 Feb 12;9:12. doi: 10.1186/1471-213X-9-12.

32.

Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma.

Lavarino C, Cheung NK, Garcia I, Domenech G, de Torres C, Alaminos M, Rios J, Gerald WL, Kushner B, LaQuaglia M, Mora J.

BMC Cancer. 2009 Feb 3;9:44. doi: 10.1186/1471-2407-9-44.

33.

Differential expression of genes mapping to recurrently abnormal chromosomal regions characterize neuroblastic tumours with distinct ploidy status.

Lavarino C, Garcia I, Mackintosh C, Cheung NK, Domenech G, Ríos J, Perez N, Rodríguez E, de Torres C, Gerald WL, Tuset E, Acosta S, Beleta H, de Alava E, Mora J.

BMC Med Genomics. 2008 Aug 13;1:36. doi: 10.1186/1755-8794-1-36.

34.

Comprehensive analysis of tumoral DNA content reveals clonal ploidy heterogeneity as a marker with prognostic significance in locoregional neuroblastoma.

Mora J, Lavarino C, Alaminos M, Cheung NK, Ríos J, de Torres C, Illei P, Juan G, Gerald WL.

Genes Chromosomes Cancer. 2007 Apr;46(4):385-96.

PMID:
17243159
35.

Use of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis.

Coma S, Noe V, Lavarino C, Adán J, Rivas M, López-Matas M, Pagan R, Mitjans F, Vilaró S, Piulats J, Ciudad CJ.

Oligonucleotides. 2004;14(2):100-13.

PMID:
15294074
36.

Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors.

Birindelli S, Perrone F, Oggionni M, Lavarino C, Pasini B, Vergani B, Ranzani GN, Pierotti MA, Pilotti S.

Lab Invest. 2001 Jun;81(6):833-44.

PMID:
11406645
37.

Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas.

Tamborini E, Della Torre G, Lavarino C, Azzarelli A, Carpinelli P, Pierotti MA, Pilotti S.

Int J Cancer. 2001 Jun 15;92(6):790-6.

38.

p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma.

Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, Mangioni C, Lucchini V, Vecchione F, Bolis G, Scarfone G, Zunino F.

J Clin Oncol. 2000 Dec 1;18(23):3936-45.

PMID:
11099323
39.

Dedifferentiation in salivary gland carcinomas.

Di Palma S, Corletto V, Lavarino C, Birindelli S, Pilotti S.

Am J Surg Pathol. 2000 Oct;24(10):1439-40. No abstract available.

PMID:
11023111
40.

Biochemical uncovering of mdm2/p53 complexes in liposarcomas parallels their immunohistochemical detection.

Butò S, Pierotti MA, Tamborini E, Della Torre G, Lavarino C, Rilke F, Pilotti S.

Diagn Mol Pathol. 1999 Sep;8(3):125-30.

PMID:
10565683
41.

TP53 mutation in mucinous carcinoma of the breast.

Di Palma S, Lavarino C, Oggionni M, Pilotti S.

Histopathology. 1999 Jun;34(6):559-60. No abstract available.

PMID:
10383705
42.

Unilateral aneuploid dedifferentiated acinic cell carcinoma associated with bilateral-low grade diploid acinic cell carcinoma of the parotid gland.

Di Palma S, Corletto V, Lavarino C, Birindelli S, Pilotti S.

Virchows Arch. 1999 Apr;434(4):361-5.

PMID:
10335948
43.

Limited role of TP53 and TP53-related genes in myxoid liposarcoma.

Pilotti S, Lavarino C, Mezzelani A, Della Torre C, Minoletti F, Sozzi G, Azzarelli A, Rilke F, Pierotti MA.

Tumori. 1998 Sep-Oct;84(5):571-7.

PMID:
9862519
44.

Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22.

Pilotti S, Della Torre G, Lavarino C, Sozzi G, Minoletti F, Vergani B, Azzarelli A, Rilke F, Pierotti MA.

J Pathol. 1998 Jun;185(2):188-90.

PMID:
9713346
45.

Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma.

Lavarino C, Corletto V, Mezzelani A, Della Torre G, Bartoli C, Riva C, Pierotti MA, Rilke F, Pilotti S.

Br J Cancer. 1998;77(1):125-30.

46.

p53 in drug resistance in ovarian cancer.

Lavarino C, Delia D, Di Palma S, Zunino F, Pilotti S.

Lancet. 1997 May 24;349(9064):1556. No abstract available.

PMID:
9167490
47.

Distal intramural spread in adenocarcinoma of the lower third of the rectum treated with total rectal resection and coloanal anastomosis.

Andreola S, Leo E, Belli F, Lavarino C, Bufalino R, Tomasic G, Baldini MT, Valvo F, Navarria P, Lombardi F.

Dis Colon Rectum. 1997 Jan;40(1):25-9.

PMID:
9102256
48.

Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.

Pilotti S, Della Torre G, Lavarino C, Di Palma S, Sozzi G, Minoletti F, Rao S, Pasquini G, Azzarelli A, Rilke F, Pierotti MA.

J Pathol. 1997 Jan;181(1):14-24.

PMID:
9071998
49.

Total rectal resection, mesorectum excision, and coloendoanal anastomosis: a therapeutic option for the treatment of low rectal cancer.

Leo E, Belli F, Andreola S, Baldini MT, Gallino GF, Giovanazzi R, Mascheroni L, Patuzzo R, Vitellaro M, Lavarino C, Bufalino R.

Ann Surg Oncol. 1996 Jul;3(4):336-43.

PMID:
8790845
50.

A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.

Righetti SC, Della Torre G, Pilotti S, Ménard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Böhm S, Bresciani GL, Spatti G, Zunino F.

Cancer Res. 1996 Feb 15;56(4):689-93.

Supplemental Content

Loading ...
Support Center